
Alzheimer’s drug from Eisai and Biogen slows cognitive decline, side-effects in focus
By Deena Beasley SAN FRANCISCO (Reuters) -An experimental Alzheimer’s drug from Eisai and Biogen slo...
30th November, 2022

By Deena Beasley SAN FRANCISCO (Reuters) -An experimental Alzheimer’s drug from Eisai and Biogen slo...
30th November, 2022

By Nick Carey LONDON (Reuters) – The UK’s car lobby on Tuesday called on the government to take urge...
29th November, 2022

By Ove Kreison, CTO at Estonian core banking provider Tuum. Digital transformation has dominated ind...
29th November, 2022

Publicis Groupe APAC will roll out attention-based approaches across their clients’ digital ad campa...
29th November, 2022

The leader in micro-moment advertising continues on its growth trajectory with another senior hire L...
29th November, 2022

Groundbreaking ad tech company continues on its mission to help advertisers optimise campaigns, redu...
29th November, 2022

Continued expansion at Lumen comes as it offers increasing numbers of clients with ground-breaking a...
29th November, 2022

By Supantha Mukherjee STOCKHOLM (Reuters) – More than 1,000 technology startups were created in Euro...
29th November, 2022

By Heekyong Yang and Joyce Lee SEOUL (Reuters) – South Korea’s Hyundai Motor Group has signed an agr...
29th November, 2022

By Ralf Gladis, CEO, Computop The economic outlook for the year ahead is unclear but this will not s...
29th November, 2022

By Glenn Griggs, Board Director of Sales at Ricoh UK, looks at the increasing importance of digital...
29th November, 2022

By Jonathan Power, RVP Northern Europe, Backbase There is no denying that the current financial land...
29th November, 2022